Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc (Q44099445)
Jump to navigation
Jump to search
scientific article published in July 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc |
scientific article published in July 2002 |
Statements
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate) (English)
Michael Untch
1 reference
Peter Schmid
Diethelm Wallwiener
Valentin Kossé
Grigorij Bondar
Leonid Vassiljev
Valerie Tarutinov
Erika Kienle
Diana Lüftner
Kurt Possinger
TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate)